Stablon scientific update |
|
 |
|
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(3):20-5.
Levin OS.
[Coaxil (tianeptine) in the treatment of depression in Parkinson's disease] [Article in Russian]
Clinical evaluation of tianeptine (coaxil) efficacy and safety has been conducted in an open non-comparison study of 18 patients with Parkinson's disease (PD) with moderate and marked depressive symptoms measured by Hamilton and Beck depression scales. To the end of the 3rd month of the treatment, scores on the Hamilton Depression Scale (HAM-D) decreased by 34% and by 31% on the Beck Depression Scale (p<0.05) as compared to the baseline level. Improvement was observed in 14 out of 18 patients (77%), with decreasing of HAM-D scores by 50% and over in 8 patients (44%). An analysis of depressive symptoms structure revealed that the improvement was due to the decrease of anxiety and somatoform symptoms and, to a lesser extent, to melancholy and sleep disorders. However, a level of apathy did not change. The decrease of depression was accompanied by significant improvement of quality of life. The efficacy of coaxil was higher in patients with less marked depressive and motor symptoms, shorter disease course and less cognitive impairment. Good tolerability of coaxil was observed during the whole study. Therefore, coaxil may be recommended for treatment of depressive symptoms in patients with PD.
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1337-9.
Ozalp E, Soygur H, Cankurtaran ES, Turhan L, Cekic T, Akarsu ES, Palaoglu O, Ayhan IH.
Ankara Oncology Training and Research Hospital, Psychiatry Clinic, Kolej, Ankara, Turkey.
Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report.
It is not scarce that patients experience various extrapyramidal symptoms (EPS) during antidepressant drug therapy. Thus, choice of an antidepressant drug in case of extrapyramidal side effects, at present, is a dilemma. Escitalopram, which is a recently marketed selective serotonin reuptake inhibitors (SSRI), has no such reputation. There is just one case reported for tianeptine that induced abnormal involuntary movements/extrapyramidal side effects. We would like to present a case that was successfully managed with bupropion which had developed EPS during 2 different SSRI (sertraline and escitalopram) and tianeptine therapy.
Neuropsychopharmacology. 2007 Feb;32(2):412-6.
Uzbay TI, Kayir H, Ceyhan M.
Department of Medical Pharmacology, Psychopharmacology Research Unit, Gulhane Military Medical Academy, Ankara, Turkey.
Effects of tianeptine on onset time of pentylenetetrazole-induced seizures in mice: possible role of adenosine A1 receptors.
Depression is a common psychiatric problem in epileptic patients. Thus, it is important that an antidepressant agent has anticonvulsant activity. This study was organized to investigate the effects of tianeptine, an atypical antidepressant, on pentylenetetrazole (PTZ)-induced seizure in mice. A possible contribution of adenosine receptors was also evaluated. Adult male Swiss-Webster mice (25-35 g) were subjects. PTZ (80 mg/kg, i.p.) was injected to mice 30 min after tianeptine (2.5-80 mg/kg, i.p.) or saline administration. The onset times of 'first myoclonic jerk' (FMJ) and 'generalized clonic seizures' (GCS) were recorded. Duration of 600 s was taken as a cutoff time in calculation of the onset time of the seizures. To evaluate the contribution of adenosine receptors in the effect of tianeptine, a nonspecific adenosine receptor antagonist caffeine, a specific A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a specific A2A receptor antagonist 8-(3-chlorostyryl) caffeine (CSC) or their vehicles were administered to the mice 15 min before tianeptine (80 mg/kg) or saline treatments. Tianeptine (40 and 80 mg/kg) pretreatment significantly delayed the onset time of FMJ and GCS. Caffeine (10-60 mg/kg, i.p.) dose-dependently blocked the retarding effect of tianeptine (80 mg/kg) on the onset times of FMJ and GCS. DPCPX (20 mg/kg) but not CSC (1-8 mg/kg) blocked the effect of tianeptine (80 mg/kg) on FMJ. Our results suggest that tianeptine delayed the onset time of PTZ-induced seizures via adenosine A1 receptors in mice. Thus, this drug may be a useful choice for epileptic patients with depression.
J Sex Med. 2006 Sep;3(5):910-7.
El-Shafey H, Atteya A, el-Magd SA, Hassanein A, Fathy A, Shamloul R.
Department of Andrology, Sexology and STDs, Cairo University, New Maadi, Cairo, Egypt.
Tianeptine can be effective in men with depression and erectile dysfunction.
INTRODUCTION: Erectile dysfunction (ED) and depression are highly prevalent medical disorders affecting men of diverse cultures throughout the world. Tianeptine is a new antidepressant drug with less adverse effects on sexual functions. AIM: To evaluate the efficacy of tianeptine in the treatment of mild to moderate depression with ED. METHODS AND MAIN OUTCOME MEASURES: A randomized, double-blind, placebo-controlled, crossover trial. Subjects were assigned either tianeptine or matching placebo, each for 8 weeks. All patients were followed up on monthly basis where they were asked to complete three assessment questionnaires, namely, Anxiety and Depression Scale, Brief Sexual Inventory, and Quality-of-life and erection questionnaire. All patients were asked a global assessment question. Treatment-responsive subjects were defined as study participants who had scores 1-16 on the Anxiety and depression Scale, showed normal erectile function on the Brief Sexual Inventory, and answered "yes" to the global assessment question. RESULTS: Of the 237 consecutive men complaining of ED of >6 months and screened for this study, 110 patients met our inclusive criteria; 42 declined to participate. The remaining 68 patients were randomly assigned to treatment. Significant improvement (P < 0.05) was observed during the active drug phase in all three assessments questionnaires, in comparison with the placebo phase. Forty-eight patients (72.7%) of the subjects during the active drug phase were classified as responders, while 19 (27.9%) of the subjects during placebo phase were classified as responders. CONCLUSIONS: Tianeptine could be considered an effective therapy for the treatment of depression and ED. Further large-scale multicentered studies are warranted.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):776-8.
Kisa C, Bulbul DO, Aydemir C, Goka E.
Department of Psychiatry, Ankara Numune Hospital, Turkey.
Is it possible to be dependent to Tianeptine, an antidepressant? A case report.
Tianeptine, an atypical tricyclic antidepressant, is one of the first chemical agents, like tricyclic antidepressants and selective serotonin re-uptake inhibitors (SSRIs), which are employed for the treatment of anxiety and depressive disorders. It is believed that tianeptine, unlike the SSRIs, is enhancing serotonin re-uptake the velocity of the cortical neurons in the lymbic system and hippocampal neurons. In literature, there are more examples of dependence cases of antidepressants, which have amphetaminergic effects, such as amineptine and tranylcipromine, than amitriptyline, fluoxetine and tianeptine. Contrary to the reports about using high dosages of tianeptine, case reports about misuse and dependence have revealed that the most common reason of dependence is the psychostimulant effect. In these cases, tolerance to tianeptine and the symptoms of depreviation in absence of the drug have been seen, and the history of dependence or abuse of any drug or alcohol, treatment for mood and/or personality disorders are mentioned as possible risks for the dependence to tianeptine. This report discusses the diagnosis and treatment of a tianeptine dependence case. The 34 year-old patient, who is in conflict with her own family members, does not have the history of dependence or abuse of any substances, except for smoking, had been using excessive doses of 750 mg/day of tianeptine for a year.
Neurosci Behav Physiol. 2007 May;37(4):419-24.
Levin OS.
Department of Neurology, Russian Medical Academy of Postgraduate Education, Center for Extrapyramidal Diseases, Federal Health Agency, Moscow, Russia.
Coaxil (tianeptine) in the treatment of depression in Parkinson's disease.
An open, non-comparative clinical study was performed to assess the efficacy and safety of tianeptine (Coaxil) in Parkinson's disease (PD). A total of 18 patients with PD were used whose clinical state increased moderately severe and more profound depression (assessed on the Hamilton and Beck scales). After three months of treatment, depression on the Hamilton depression scale was decreased by 34% and on the Beck scale by 31% compared with baseline data ((p) < 0.05). Improvements in mental status were noted in 14 of 18 patients (77%); eight patients (44%) showed more than 50% reductions on the Hamilton scale. Analysis of the structure of depressive symptomatology showed that improvement occurred because of decreases in anxiety and the severity of somatoform symptoms and, to a lesser extent, in melancholy and sleep disturbance. There was no significant change in apathy. The decrease in the severity of depression was accompanied by an improvement in the quality of life. The efficacy of Coaxil was greater in patients with less marked depressive and motor symptoms, shorter durations of illness, and less marked cognitive impairments. Coaxil was well tolerated by the patients. The data obtained here provide grounds for recommending the use of Coaxil in the treatment of depression in PD.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):915-24.
Uzbay TI.
Gulhane Military Medical Academy, Department of Medical Pharmacology, Psychopharmacology Research Unit, Etlik 06018 Ankara, Turkey.
Tianeptine: potential influences on neuroplasticity and novel pharmacological effects.
Tianeptine is an atypical antidepressant drug. In contrast to tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), it has been suggested that tianeptine decreases serotonin's activity and amount in serotonergic synapses of the central nervous system by increasing serotonin reuptake. Tianeptine, which has a mechanism of action opposite to that of SSRIs, necessitated a re-evaluation of the biochemical basis of depression and revealed that it cannot be explained by the monoamine hypothesis only. Recent studies by tianeptine have been focused on neuroplasticity. Neuroplasticity hypothesis of depression has the potential to make important contributions to the diagnosis, as well as it may be helpful in the explanation of the drug effects, which cannot be explained by neurochemical mechanisms. In addition, recent interesting results indicating anticonvulsant and analgesic activity of tianeptine and its possible interaction with adenosine A(1) receptors were obtained. In this review, novel central actions of tianeptine and the relationship between stress, neuroplasticity and drug effects were evaluated in the light of the current literature.
Recent Patents CNS Drug Discov. 2006 Jan;1(1):29-41.
Brink CB, Harvey BH, Brand L.
Division of Pharmacology, North-West University (PUK), Potchefstroom, 2520, South Africa.
Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression.
Tianeptine, an atypical antidepressant patented and developed by Servier, enhances the synaptic reuptake of serotonin, without affecting norepinephrine and dopamine uptake, while it lacks affinity for neurotransmitter receptors. This mechanism for an antidepressant is apparently paradoxical, since the currently employed antidepressants enhance serotonin by inhibiting its breakdown or by inhibiting monoaminergic reuptake. Although tianeptine has been shown to reduce central 5HT availability and to indirecty modulate central adrenergic and dopaminergic systems and to indirectly inhibit cholinergic hyperactivity, its antidepressant action is believed to be more directly related to central neuronal remodeling and restoration of neuronal plasticity. In reliable animal models of depression tianeptine has been shown to prevent neurodegeneration and decreases in hippocampal volume in response to chronic stress. These effects on neuroplasticity are suspected to involve the normalization of the hypothalamic-pituitary-adrenal axis and modulatory effects on excitatory amino acids and N-methyl-D-aspartate receptors. Together with a body of related studies, these data provide further support for the hypothesis that depression may involve dysregulation of pathways controlling cellular resilience and that treatment should be directed towards the reversal thereof. Importantly, tianeptine is not anxiogenic and has also been shown to be effective in treatment-resistant depression, which may lead the way to a major breakthrough in the treatment of depression.
Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(1):36-9.
[The use of coaxil (tianeptine) in the treatment of aged people with combined mild cognitive impairment and depressive-anxiety disorders] [Article in Russian]
Twenty patients, aged 60-69 years, with combined mild cognitive impairment, subtle depression and anxiety have been treated with coaxil (tianeptine) used in dosage 37,5 mg daily during 60 days. The clinical state of patients has been assessed using clinical-psychopathological examination as well as the Hamilton scale and neuropsychological testing according to A.R. Luria. The high effectiveness of coaxil is revealed with respect to all psychopathological characteristics. Recommendations on expediency of administering coaxil to aged patients with combined cognitive and depressive disorders are presented.
Stablon description...
|
|
Drug category:Antidepressants
 Stablon scientific update
|
|
My Basket